Blueprint Medicines Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Blueprint Medicines

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: tuck who wrote (11)	12/3/2018 8:25:01 AM
From: atticus4paws	of 12

Thanks Tuck! A couple of things I'm wondering... Will they design the P2 for possible approval? It should be possible to demonstrate efficacy with smallish numbers, but as it will be a chronic drug, does long term safety become the dominant consideration? Regarding prevalence (my mind gets turned around with incidence sometimes - not today)... If we assume that BPMC has estimated correctly in the U.S. (~8500 across all SM types) and that number will be fairly steady with population changes and they capture the entire market, wouldn't it still necessitate a hefty price tag to make this drug much of an earner in SM?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext